NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors
30 March 2020 - 10:05PM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced the appointment of Garry
Nicholson to its board of directors. Mr. Nicholson has more than 30
years of product development and commercialization experience and
previously held leadership positions at Pfizer Oncology and Eli
Lilly and Company. In addition, Timothy M. Shannon, M.D. notified
NextCure that he is stepping down from the company’s board of
directors.
“Garry is a highly-regarded industry leader and
brings deep expertise in developing and commercializing oncology
products. We expect that his guidance and advice will greatly
support NextCure as we continue to grow our company and advance our
clinical programs,” said Michael Richman, president and chief
executive officer. “His deep knowledge and expertise in drug
development, business development, corporate strategy and marketing
will enhance our capabilities in developing and commercializing
novel immunomedicines for cancer patients. We would like to thank
Tim Shannon for his commitment and support as a founding Director
in building NextCure from its inception,” Mr. Richman added.
Mr. Nicholson currently serves as chairman of the
board for G1 Therapeutics and as a board member for Turning Point
Therapeutics, Five Prime Therapeutics, Personal Genome Diagnostics
and Tmunity Therapeutics. He previously served on the TESARO board
prior to its acquisition by GlaxoSmithKline and as president and
CEO of XTuit Pharmaceuticals. Prior to that, he was President of
Pfizer Oncology, where he oversaw global commercialization and
sales, clinical development, regulatory and business strategies. He
has also held various leadership positions in the oncology division
of Eli Lilly and Company. Mr. Nicholson holds an M.B.A. from the
University of South Carolina and a B.S. in Pharmacy from the
University of North Carolina at Chapel Hill.
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases. Through our proprietary
FIND-IO™ platform, we study various immune cells to discover and
understand targets and structural components of immune cells and
their functional impact in order to develop immunomedicines. Our
initial focus is to bring hope and new treatments to patients who
do not respond to current cancer therapies, patients whose cancer
progresses despite treatment and patients with cancer types not
adequately addressed by available therapies. www.nextcure.com
Forward-Looking
StatementsStatements made in this press release that are
not historical facts are forward-looking statements. Words such as
“expects,” “believes,” “intends,” “hope,” “forward” and similar
expressions are intended to identify forward-looking statements.
Examples of forward-looking statements in this press release
include, among others, statements about NextCure’s plans,
objectives and intentions with respect to the discovery of
immunomedicine targets and the discovery and development of
immunomedicines. Forward-looking statements involve substantial
risks and uncertainties that could cause actual results to differ
materially from those projected in any forward-looking statement.
Such risks and uncertainties include, among others: our limited
operating history and no products approved for commercial sale; our
history of significant losses; our need to obtain additional
financing; risks related to clinical development, marketing
approval and commercialization; and the unproven approach to the
discovery and development of product candidates based on our
FIND-IO platform. More detailed information on these and additional
factors that could affect NextCure’s actual results are described
in NextCure’s filings with the Securities and Exchange Commission
(the “SEC”), including in the Risk Factors section and throughout
NextCure’s Form 10-K filed with the SEC on March 12, 2020. You
should not place undue reliance on any forward-looking statements.
NextCure assumes no obligation to update any forward-looking
statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 591-3481
NextCure@macbiocom.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Sep 2023 to Sep 2024